Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Recurrence 2Lymphoma, B-Cell 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Erectile Dysfunction 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 59Cisplatin 45Cetuximab 29Radiotherapy 26Carboplatin 24Docetaxel 17Paclitaxel 16Nivolumab 16Surveys and Questionnaires 15Radiotherapy, Intensity-Modulated 13Fluorouracil 12Drug Therapy 12Blood Specimen Collection 11Standard of Care 8tislelizumab 7cemiplimab 6atezolizumab 6Radiation 6Chemoradiotherapy 6toripalimab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5nimotuzumab 4fludarabine 4durvalumab 4dostarlimab 4Surgical Procedures, Operative 4Afatinib 4palbociclib 3niraparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Cell- and Tissue-Based Therapy × 1 year × Clear all
NCT06096038 2026-02-20

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
33 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡